{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:39:11Z","timestamp":1787071151178,"version":"build-2736575974"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11]]},"abstract":"Abstract<\/jats:title>\n \n Background:<\/jats:title>\n The first line of therapy for limited patchy alopecia areata is topical corticosteroids. Recently, topical methotrexate has been found effective in alopecia areata.<\/jats:p>\n <\/jats:sec>\n \n Objective:<\/jats:title>\n To compare the efficacy between topical methotrexate and betamethasone dipropionate lotion in the treatment of localized scalp alopecia areata.<\/jats:p>\n <\/jats:sec>\n \n Patients and Methods:<\/jats:title>\n Seventy patients with localized scalp alopecia areata were randomized by block randomization in a 1:1 ratio to two groups. Group A received methotrexate 1% gel twice daily, and group B received betamethasone dipropionate 0.05% lotion twice daily for 12 weeks or until a hair regrowth score of 5 was achieved.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n Fifty-six patients completed the trial. In the per-protocol analysis, no significant difference was seen in the decrease in severity of alopecia tool (SALT) score between group A and group B. The median (25\n th<\/jats:sup>\n \u201375\n th<\/jats:sup>\n percentile) modified hair regrowth scale at 4 weeks and 12 weeks in group A was 1 (0\u20132) and 4 (3.5\u20135), respectively. In group B, it was 1 (0\u20131.5) and 4 (3\u20135), respectively, with no significant difference between them. Mild and tolerable side effects were seen in both groups. Irritant dermatitis was seen in 31.03% of patients in group A. Itching was reported in 16 patients in group A as compared to 4 patients in group B, which was statistically significant (\n P<\/jats:italic>\n value = 0.002).\n <\/jats:p>\n <\/jats:sec>\n \n Limitations:<\/jats:title>\n Few patients were lost to follow-up and patients were not followed up after stopping treatment to assess the long-term treatment response or relapse.<\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n Both methotrexate gel and betamethasone lotion are effective and safe treatments for localized alopecia areata, showing comparable overall response rates. However, local side effects are more common with methotrexate gel than with betamethasone lotion. This study suggests that methotrexate gel can be considered one of the topical treatment options for localized alopecia areata.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/idoj.idoj_212_24","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T12:00:27Z","timestamp":1755259227000},"page":"946-950","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of the Efficacy of Topical Methotrexate 1% gel Versus Topical Betamethasone Dipropionate 0.05% Lotion in the Treatment of Localized Scalp Alopecia Areata in a Tertiary Care Institute of Central India: A Randomized Control Trial"],"prefix":"10.4103","volume":"16","author":[{"given":"Susmita","family":"Banra","sequence":"first","affiliation":[{"name":"Department of Dermatology, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5714-4764","authenticated-orcid":false,"given":"Neel","family":"Prabha","sequence":"additional","affiliation":[{"name":"Department of Dermatology, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0044-558X","authenticated-orcid":false,"given":"Soumil","family":"Khare","sequence":"additional","affiliation":[{"name":"Department of Dermatology, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"key":"R1-20251030","first-page":"39","article-title":"Acquired disorders of hair","author":"Messenger","year":"2016","journal-title":"Rook's textbook of dermatology"},{"key":"R2-20251030","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jaad.2009.10.031","article-title":"Alopecia areata update:Part II. Treatment","volume":"62","author":"AlKhalifah","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"R3-20251030","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/ijd.14898","article-title":"Topical methotrexate 1% gel for the treatment of localized alopecia areata","volume":"59","author":"Ahmed","year":"2020","journal-title":"Int J Dermatol"},{"key":"R4-20251030","doi-asserted-by":"crossref","first-page":"15696","DOI":"10.1111\/dth.15696","article-title":"Comparative study between topical methotrexate 1% gel and minoxidil 5% gel in the treatment of localized alopecia areata","volume":"35","author":"Toma","year":"2022","journal-title":"Dermatol Ther"},{"key":"R5-20251030","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jaad.2003.09.032","article-title":"National alopecia areata foundation alopecia areata investigational assessment guidelines. Part II. National alopecia areata foundatin","volume":"51","author":"Olsen","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"R6-20251030","doi-asserted-by":"crossref","first-page":"42","DOI":"10.25259\/IJDVL_787_19","article-title":"A randomized comparative study of the efficacy of topical latanoprost versus topical betamethasone diproprionate lotion in the treatment of localized alopecia areata","volume":"87","author":"Bhat","year":"2021","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R7-20251030","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1080\/09546634.2020.1770170","article-title":"Topical methotrexate in dermatology:A review of the literature","volume":"33","author":"Aickara","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"R8-20251030","doi-asserted-by":"crossref","first-page":"13013","DOI":"10.1111\/dth.13013","article-title":"Topical methotrexate 1% gel for treatment of vitiligo:A case report and review of the literature","volume":"32","author":"Abdelmaksoud","year":"2019","journal-title":"Dermatol Ther"},{"key":"R9-20251030","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1046\/j.1365-4362.2001.01244.x","article-title":"A clinical study to determine the efficacy and safety of 1% methotrexate\/azone (MAZ) gel applied topically once daily in patients with psoriasis vulgaris","volume":"40","author":"Sutton","year":"2001","journal-title":"Int J Dermatol"},{"key":"R10-20251030","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jaad.2018.06.064","article-title":"Methotrexate for alopecia areata:A systematic review and meta-analysis","volume":"80","author":"Phan","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"R11-20251030","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1046\/j.1365-4362.2003.01862.x","article-title":"Efficacy of betamethasone valerate foam formulation in comparison with betamethasone dipropionate lotion in treatment of mild to moderate alopecia areata:Multicentric, prospective, randomized, controlled, investigator-blinded trial","volume":"42","author":"Mancuso","year":"2003","journal-title":"Int J Dermatol"},{"key":"R12-20251030","first-page":"891","article-title":"Methotrexate for topical application in an extemporaneous preparation","volume":"13","author":"Wohlrab","year":"2015","journal-title":"J Dtsch Dermatol Ges"},{"key":"R13-20251030","doi-asserted-by":"crossref","first-page":"563","DOI":"10.4103\/0378-6323.116725","article-title":"Alopecia areata:An update","volume":"79","author":"Seetharam","year":"2013","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"62","key":"R14-20251030","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jaad.2009.10.032","article-title":"Alopecia areata update:Part I. Clinical picture, histopathology, and pathogenesis","volume":"1","author":"Alkhalifah","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"R15-20251030","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1067\/mjd.2000.103909","article-title":"Alopecia areata update","volume":"42","author":"Madani","year":"2000","journal-title":"J Am Acad Dermatol"}],"container-title":["Indian Dermatology Online Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/idoj.idoj_212_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:42:16Z","timestamp":1787067736000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/idoj.idoj_212_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/idoj.idoj_212_24","relation":{},"ISSN":["2229-5178","2249-5673"],"issn-type":[{"value":"2229-5178","type":"print"},{"value":"2249-5673","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,14]]},"assertion":[{"value":"2024-03-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}